Atrial fibrillation raises the risk of stroke, heart failure, dementia and death [12]. Anticoagulation prevents most of the excess stroke risk, so the decision for each patient turns on the absolute risk of stroke and thromboembolism, the risk of bleeding, and the net clinical benefit between them [4]. The ESC 2024 guideline [1], the 2023 ACC/AHA/ACCP/HRS guideline [2] and the CHEST guideline [3] agree on the framework, although they score risk slightly differently.
The pattern of atrial fibrillation does not change the decision: paroxysmal, persistent and permanent atrial fibrillation are treated alike for stroke prevention, and a return to sinus rhythm after cardioversion or ablation is not on its own a reason to stop anticoagulation.